user

NCCTG phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM).

被引：0
|
作者：
Galanis, E
Buckner, JC
Maurer, M
Ballman, K
Hidalgo, M
Kreisberg, JI
Boni, J
James, CDD
Jenkins, RB
Walsh, DJ
机构：
[1] Mayo Clin, Coll Med, Rochester, MN USA
[2] Johns Hopkins Univ, Baltimore, MD USA
[3] UTHSCSA, San Antonio, TX USA
[4] N Cent Canc Treatment Grp, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1503
引用
收藏
页码：107S / 107S
页数：1
相关论文
共 50 条
  • [41] Phase I Trial of CCI-779 (Temsirolimus) and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma.
    Ghobrial, Irene M.
    Munshi, Nikhil
    Schlossman, Robert
    Chuma, Stacey
    Leduc, Renee
    Nelson, Marybeth
    Sam, Amy
    O'Connor, Kelly
    Harris, Brianna
    Warren, Diane
    Dollard, Akari M.
    Laubach, Jacob
    Vij, Ravi
    Campagnaro, Erica
    Birner, Ann
    Dixon-Lipscomb, Virginia
    Anderson, Kenneth C.
    Richardson, Paul G.
    BLOOD, 2008, 112 (11) : 1266 - 1266
  • [42] Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034
    Van den Bent, Martin
    Brandes, Alba
    Rampling, Roy
    Kouwenhoven, Mathilde
    Kros, Johan M.
    Carpentier, Antoine
    Clement, Paul
    Klughammer, Barbara
    Bakker, Brenda
    Lacombe, Denis
    Gorlia, Thierry
    NEURO-ONCOLOGY, 2007, 9 (04) : 522 - 522
  • [43] Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034
    Van Den Bent, M. J.
    Brandes, A.
    Rampling, R.
    Kouwenhoven, M.
    Kros, J. M.
    Carpentier, A. F.
    Clement, P.
    Klughammer, B.
    Gorlia, T.
    Lacombe, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [44] Fotemustine in recurrent or progressive glioblastoma multiforme (GBM)
    Savio, G.
    Pepe, A.
    Laudani, A.
    Leonardi, V
    Usset, A.
    Rondello, G.
    Arcuri, C.
    Palmisano, V
    Alu', M.
    Macaluso, M.
    Agostara, B.
    ANNALS OF ONCOLOGY, 2007, 18 : 80 - 80
  • [45] Phase II trial of thalidomide in combination with irinotecan in adults with recurrent glioblastoma multiforme
    Puduvalli, VK
    Giglio, P
    Groves, MD
    Hess, KR
    Jackson, E
    Mahankali, S
    Gilbert, M
    Levin, VA
    Conrad, C
    Hsu, S
    Yung, WKA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 120S - 120S
  • [46] Phase II trial of irinotecan and thalidomide in adult patients with recurrent glioblastoma multiforme
    Puduvalli, V. K.
    Giglio, P.
    Groves, M. D.
    Hess, K. R.
    Gilbert, M. R.
    Mahankali, S.
    Jackson, E.
    Levin, V. A.
    Conrad, C. A.
    Hsu, S.
    Colman, H.
    Ritterhouse, M.
    Ichtech, S.
    Yung, W. K. A.
    NEURO-ONCOLOGY, 2006, 8 (04) : 450 - 450
  • [47] NCCTG PHASE II TRIAL OF BEVACIZUMAB IN COMBINATION WITH SORAFENIB (BEV/SOR) IN RECURRENT GLIOBLASTOMA (rGBM)
    Galanis, Evanthia
    Anderson, S. Keith
    Lafky, Jacqueline M.
    Kaufmann, Timothy J.
    Uhm, Joon H.
    Giannini, Caterina
    Kumar, Shaji K.
    Northfelt, Donald W.
    Flynn, Patrick J.
    Jaeckle, Kurt A.
    Buckner, Jan C.
    NEURO-ONCOLOGY, 2011, 13 : 62 - 62
  • [48] Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs
    Susan M. Chang
    John Kuhn
    Patrick Wen
    Harry Greenberg
    David Schiff
    Charles Conrad
    Karen Fink
    H. Ian Robins
    Timothy Cloughesy
    Lisa De Angelis
    Jeffrey Razier
    Kenneth Hess
    Janet Dancey
    Michael D. Prados
    Investigational New Drugs, 2004, 22 : 427 - 435
  • [49] Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs
    Chang, SM
    Kuhn, J
    Wen, P
    Greenberg, H
    Schiff, D
    Conrad, C
    Fink, K
    Robins, HI
    Cloughesy, T
    De Angelis, L
    Razier, J
    Hess, K
    Dancey, J
    Prados, MD
    INVESTIGATIONAL NEW DRUGS, 2004, 22 (04) : 427 - 435
  • [50] Phase II trial of high dose imatinib in recurrent glioblastoma multiforme (GBM) with platelet derived growth factor receptor (PDGFR) expression
    Viola, F. S.
    Katz, A.
    Arantes, A.
    Gaiger, A.
    Vasconcellos, C.
    Passos, V.
    Barrios, C. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345